First EMIF-AD genome-wide association study published

22. November 2020

This month the first genome-wide association study (GWAS) to emerge from the EMIF-AD MBD project was published today in the journal Translational Psychiatry. The paper describes the results of genome-wide genetic association analyses on a total of 16 Alzheimer’s disease biomarker traits (most derived from cerebrospinal fluid) in 931 participants of the European Medical Information Framework Alzheimer’s Disease Multimodal Biomarker Discovery (EMIF-AD MBD). The study was funded by the EU’s EMIF program and designed and executed by the LIGA team in conjunction with a large number of international collaborators. A preprint of the m.s. had been posted earlier on bioRxiv prior to initiating the peer-review process. The study represents a detailed first account of GWAS analyses on CSF-Aβ and -tau-related traits in the EMIF-AD MBD dataset and sets the stage for genome-wide analyses of other AD-relevant clinical outcomes ascertained in this unique dataset.